Anticancer, hepatoprotective, and mechanistic evidence of chlorogenic acid in liver cancer: A systematic review.

Biomed PharmacotherJul 17, 2026 (epub)
Clinical ResearchOncology (Medical)Gastroenterology

Amaya Pérez Pérez, Felipe Zamorano Peña, Keila Torres et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effects of chlorogenic acid (CGA) on liver cancer, analyzing 21 studies. CGA showed anticancer effects in preclinical models by inhibiting tumor cell proliferation and inducing apoptosis. The review highlights CGA's potential as a hepatoprotective agent, although most evidence is preclinical and further research is needed.

Key findings

  • CGA inhibits tumor cell proliferation, migration, and invasion in liver cancer models.
  • CGA induces apoptosis and ferroptosis through AMPK, ERK, and other pathways.
  • CGA enhances the efficacy of certain chemotherapeutic agents, with noted antagonistic effects in radiotherapy.

Why it matters

Understanding the potential of CGA in liver cancer could inform future therapeutic strategies, especially given the high mortality associated with hepatocellular carcinoma. Its multi-target mechanisms may offer new avenues for treatment.

Source

PubMed · PMID 42468210

Published in Biomed Pharmacother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.